Psoriatic Arthritis Trial, Recruiting NCT05754710 Sponsor: Pfizer Condition: Psoriatic Arthritis
Back to Psoriatic Arthritis

Psoriatic Arthritis Trial, Recruiting

NCT05754710
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children and teenagers aged 2 years old up to (but not including) 18 years old
  • People whose doctor has decided to prescribe Xeljanz based on their medical judgement and in line with the approved prescribing guidelines
  • People for whom Xeljanz has been prescribed according to its approved, labelled use for their condition
  • People (and their legal guardian or representative, where applicable) who have been fully informed about the study and have signed and dated a consent form agreeing to take part

Who may not be able to join:

  • Children or teenagers for whom Xeljanz is not recommended or is considered unsafe according to the most recently approved prescribing guidelines (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
12 April 2024
Est. completion
30 September 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Number of patients with treatment emergent treatment-related adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov